The team then synthesized a lysin from a bacteriophage, or virus that attacks bacteria, that infects S. hominis.

The results led the FDA to designate the lysin, known as exebacase, a “breakthrough therapy,” meaning it will be fast-tracked for approval if a phase 3 trial, now underway, bears out the findings.

The difference is often greater when using weaker solutions than when using stronger dilutions of lysin.

By adding another fractional protein, lysin, the rats were made to thrive.

During in vitro experiments, this lysin was found to target only S. hominis, not other bacteria normally present on the skin.